Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.55 |
| ▸ | MARS1 | P56192 | 5/20 | 0.43 |
| ▸ | GCG | P01275 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13783715 | 1.00 | SRD5A2 (0.55) | SRD5A2MARS1GCGGCGRALPL | |
| SCHEMBL13783720 | 0.99 | SRD5A2 (0.56) | SRD5A2MARS1GCGGCGRALPL | |
| SCHEMBL13783737 | 0.89 | HSD17B3 (0.54) | SRD5A2MARS1GCGRCNR1 | |
| SCHEMBL13670548 | 0.85 | HDAC1 (0.50) | L3MBTL1LMNAMAPTTDP1HDAC1 | |
| SCHEMBL13670549 | 0.83 | GSK3B (0.50) | L3MBTL1LMNAMAPTTDP1HDAC1 | |
| SCHEMBL7009491 | 0.83 | L3MBTL1 (0.53) | L3MBTL1LMNAMAPTTDP1HDAC1 | |
| SCHEMBL11757895 | 0.82 | SRD5A2 (0.61) | SRD5A2MARS1GCGGCGRLMNA | |
| SCHEMBL4296972 | 0.82 | SRD5A2 (0.51) | SRD5A2MARS1GCGGCGRMCHR1 | |
| SCHEMBL4304314 | 0.82 | SRD5A2 (0.47) | SRD5A2MARS1GCGGCGRALPL | |
| SCHEMBL20998262 | 0.82 | HSD17B3 (0.41) | L3MBTL1LMNAMAPTTDP1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240094221-A1 | METHOD FOR PREDICTING THE FERTILITY POTENTIAL OF A FEMALE SUBJECT | RIGSHOSPITALET (DK) | 2024-03-21 | — | — | US | claimed |
| EP-4260069-A1 | METHOD FOR PREDICTING THE FERTILITY POTENTIAL OF A FEMALE SUBJECT | Rigshospitalet (DK) | 2023-10-18 | — | — | EP | claimed |
| CN-116829954-A | Method for predicting fertility potential of female subjects | 里格舒斯匹塔里特医院 | 2023-09-29 | — | — | CN | claimed |
| WO-2022122104-A1 | METHOD FOR PREDICTING THE FERTILITY POTENTIAL OF A FEMALE SUBJECT | RIGSHOSPITALET (DK) | 2022-06-16 | — | — | WO | claimed |
| US-12048744-B2 | RANKL-specific agent for treating metastatic disease | PROBIOCON GMBH (CH) | 2024-07-30 | — | — | US | disclosed |
| US-20240094221-A1 | METHOD FOR PREDICTING THE FERTILITY POTENTIAL OF A FEMALE SUBJECT | RIGSHOSPITALET (DK) | 2024-03-21 | — | — | US | disclosed |
| EP-4260069-A1 | METHOD FOR PREDICTING THE FERTILITY POTENTIAL OF A FEMALE SUBJECT | Rigshospitalet (DK) | 2023-10-18 | — | — | EP | disclosed |
| CN-116829954-A | Method for predicting fertility potential of female subjects | 里格舒斯匹塔里特医院 | 2023-09-29 | — | — | CN | disclosed |
| WO-2022122104-A1 | METHOD FOR PREDICTING THE FERTILITY POTENTIAL OF A FEMALE SUBJECT | RIGSHOSPITALET (DK) | 2022-06-16 | — | — | WO | disclosed |
| US-20210128722-A1 | RANKL-SPECIFIC AGENT FOR TREATING METASTATIC DISEASE | PROBIOCON GMBH (CH) | 2021-05-06 | — | — | US | disclosed |
| US-10806786-B2 | RANKL-specific agent for treating metastatic disease | PROBIOCON GMBH (CH) | 2020-10-20 | — | — | US | disclosed |
| US-20190218302-A1 | ANTI-CANCER COMBINATION TREATMENT | UNIVERSITÄTSKLINIKUM TÜBINGEN (DE) | 2019-07-18 | — | — | US | disclosed |
| US-20170319687-A1 | RANKL-SPECIFIC AGENT FOR TREATING METASTATIC DISEASE | PROBIOCON GMBH (CH) | 2017-11-09 | — | — | US | disclosed |
| US-20170319687-A1 | RANKL-SPECIFIC AGENT FOR TREATING METASTATIC DISEASE | PROBIOCON GMBH (CH) | 2017-11-09 | — | — | US | disclosed |
| US-7560597-B2 | 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-07-14 | — | — | US | disclosed |
| US-7560597-B2 | 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-07-14 | — | — | US | disclosed |
| US-7560597-B2 | 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-07-14 | — | — | US | disclosed |
| US-20080221220-A1 | 2',4'-DICHLORO-BIPHENYL-4-YL-HYDROXY-KETONES AND RELATED COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-09-11 | — | — | US | disclosed |
| US-20080221220-A1 | 2',4'-DICHLORO-BIPHENYL-4-YL-HYDROXY-KETONES AND RELATED COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-09-11 | — | — | US | disclosed |
| US-20080221220-A1 | 2',4'-DICHLORO-BIPHENYL-4-YL-HYDROXY-KETONES AND RELATED COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12048744-B2 | RANKL-specific agent for treating metastatic disease | TNFSF11, TNFSF10, TNFRSF9 | SRD5A2 4021/4885MARS1 2580/4885GCG 3923/4885 |
| US-20170319687-A1 | RANKL-SPECIFIC AGENT FOR TREATING METASTATIC DISEASE | TNFSF11, TNFSF10, TNFRSF9 | SRD5A2 4021/4885MARS1 2580/4885GCG 3923/4885 |
| US-20210128722-A1 | RANKL-SPECIFIC AGENT FOR TREATING METASTATIC DISEASE | TNFSF11, TNFSF10, TNFRSF9 | SRD5A2 4021/4885MARS1 2580/4885GCG 3923/4885 |
| US-20190218302-A1 | ANTI-CANCER COMBINATION TREATMENT | SOST, ACP3, CSF3R | SRD5A2 3024/4885MARS1 3870/4885GCG 2885/4885 |
| US-20080221220-A1 | 2',4'-DICHLORO-BIPHENYL-4-YL-HYDROXY-KETONES AND RELATED COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | RORB, RORC, NR1H2 | SRD5A2 188/4885MARS1 4662/4885GCG 3093/4885 |
| US-10806786-B2 | RANKL-specific agent for treating metastatic disease | TNFSF11, TNFSF10, TNFRSF9 | SRD5A2 4021/4885MARS1 2580/4885GCG 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.